Eylea    (DrugBank: -)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
90網膜色素変性症2
166弾性線維性仮性黄色腫2

90. 網膜色素変性症 [臨床試験数:103,薬物数:158(DrugBank:42),標的遺伝子数:52,標的パスウェイ数:107
Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 103 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02661711
(ClinicalTrials.gov)
March 201613/1/2016Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) StudyProspective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP)Macular Oedema;Retinitis PigmentosaDrug: AfliberceptMoorfields Eye Hospital NHS Foundation TrustBayerActive, not recruiting16 YearsN/ABoth30Phase 2United Kingdom
2EUCTR2015-003723-65-GB
(EUCTR)
12/01/201606/01/2016Prospective non-randomised pilot study looking at the safety and efficacy of a drug called Eylea for patients with an eye condition called Retinitis Pigmentosa, that also have swelling at the back of the eyeAflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR) - AMOUR Retinitis Pigmentosa associated Cystoid Macular Oedema
MedDRA version: 18.1;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Moorfields Eye HospitalNULLNot Recruiting Female: yes
Male: yes
30Phase 2United Kingdom

166. 弾性線維性仮性黄色腫 [臨床試験数:11,薬物数:23(DrugBank:6),標的遺伝子数:5,標的パスウェイ数:26
Searched query = "Pseudoxanthoma elasticum", "PXE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 11 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02537054
(ClinicalTrials.gov)
September 201521/8/2015Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: AfliberceptUniversity Hospital, BonnNULLCompleted18 Years65 YearsAll15Phase 2Germany
2EUCTR2014-005263-33-DE
(EUCTR)
29/04/201526/02/2015Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticumIntravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
MedDRA version: 20.0;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: EyleaMedizinische Fakultät der Universität BonnNULLNot RecruitingFemale: yes
Male: yes
15Phase 2Germany